We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The 2025 Q2 earnings season has largely been positive so far.
PLTR and LLY both raised guidance, owing to their strong results.
Expectations for Q3 remain positive as well.
The 2025 Q2 earnings cycle is slowly winding down, which has been resilient so far.
For the 457 S&P 500 companies that have reported Q2 results as of August 13th, total earnings are up +11.6% from the same period last year on +5.8% higher revenues, with 80.5% beating EPS estimates and 78.8% beating revenue estimates.
For a much deeper view into the current earnings landscape, I invite you to view our weekly Earnings Trends report, which was just published yesterday –
So far, several companies, including Palantir (PLTR - Free Report) and Eli Lilly (LLY - Free Report) have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters.
Palantir Keeps Cruising
Palantir has rapidly become one of the top AI stocks for investors, with robust quarterly results stemming from red-hot demand paving a highly positive outlook. It crushed our quarterly expectations in near early August, posting a 15% EPS beat alongside a 7% positive sales surprise.
US commercial revenue grew 93% YoY throughout its latest quarter, with US government revenue also up an impressive 53%. Total sales grew 48% year-over-year, continuing the recent streak of outsized growth.
The company delivered a slew of guidance upgrades concerning its FY25, including revenue, US commercial revenue, adjusted income from operations, and adjusted free cash flow. Analysts adjusted their sales expectations accordingly, with the updated figure suggest 45% YoY growth.
Image Source: Zacks Investment Research
The stock remains a prime selection for those seeking high-growth AI exposure, with consensus expectations for its current fiscal year suggesting 60% EPS growth on 45% higher sales. Analysts have raised their EPS expectations across the board following the recent guidance upgrade, a bullish sign concerning near-term price action.
Image Source: Zacks Investment Research
LLY Insiders Dive In
LLY shares have faced pressure in 2025 so far, down 11% overall and widely underperforming relative to the S&P 500. But shares have shown nice life off the post-earnings lows so far, undoubtedly a positive takeaway following the guidance upgrade.
Image Source: Zacks Investment Research
LLY posted Q2 sales of $15.5 billion, up 38% YoY and reflecting a 6% surprise relative to the Zacks Consensus sales estimates. Volume growth across Zepbound and Mounjaro helped lead the positive quarter, with sales of each up 172% and 68%, respectively.
Below is a chart illustrating the company’s sales on a quarterly basis.
Image Source: Zacks Investment Research
The favorable results led LLY to increase its FY25 revenue and adjusted EPS guidance, with its gross margin also moving higher to 84.3% vs the 80.8% mark in the year-ago period. Analysts have revised EPS expectations positively following the release, a bullish sign concerning near-term price action.
Image Source: Zacks Investment Research
Several directors and the CEO have purchased shares post-earnings, likely a reflection of their confidence in the long-term outlook.
Bottom Line
The 2025 Q2 earnings season is slowly grinding to a halt, which has been largely positive so far. Earnings expectations for the current period (Q3) have trickled higher, a positive development.
And throughout the Q2 cycle, several companies – Eli Lilly (LLY - Free Report) and Palantir (PLTR - Free Report) – partly stole the spotlight, reporting strong results and upping their guidance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Guidance Watch: 2 Companies Bullishly Raising Forecasts
Key Takeaways
The 2025 Q2 earnings cycle is slowly winding down, which has been resilient so far.
For the 457 S&P 500 companies that have reported Q2 results as of August 13th, total earnings are up +11.6% from the same period last year on +5.8% higher revenues, with 80.5% beating EPS estimates and 78.8% beating revenue estimates.
For a much deeper view into the current earnings landscape, I invite you to view our weekly Earnings Trends report, which was just published yesterday –
Earnings Outlook Remains Strong & Improving: A Closer Look
So far, several companies, including Palantir (PLTR - Free Report) and Eli Lilly (LLY - Free Report) have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters.
Palantir Keeps Cruising
Palantir has rapidly become one of the top AI stocks for investors, with robust quarterly results stemming from red-hot demand paving a highly positive outlook. It crushed our quarterly expectations in near early August, posting a 15% EPS beat alongside a 7% positive sales surprise.
US commercial revenue grew 93% YoY throughout its latest quarter, with US government revenue also up an impressive 53%. Total sales grew 48% year-over-year, continuing the recent streak of outsized growth.
The company delivered a slew of guidance upgrades concerning its FY25, including revenue, US commercial revenue, adjusted income from operations, and adjusted free cash flow. Analysts adjusted their sales expectations accordingly, with the updated figure suggest 45% YoY growth.
Image Source: Zacks Investment Research
The stock remains a prime selection for those seeking high-growth AI exposure, with consensus expectations for its current fiscal year suggesting 60% EPS growth on 45% higher sales. Analysts have raised their EPS expectations across the board following the recent guidance upgrade, a bullish sign concerning near-term price action.
Image Source: Zacks Investment Research
LLY Insiders Dive In
LLY shares have faced pressure in 2025 so far, down 11% overall and widely underperforming relative to the S&P 500. But shares have shown nice life off the post-earnings lows so far, undoubtedly a positive takeaway following the guidance upgrade.
Image Source: Zacks Investment Research
LLY posted Q2 sales of $15.5 billion, up 38% YoY and reflecting a 6% surprise relative to the Zacks Consensus sales estimates. Volume growth across Zepbound and Mounjaro helped lead the positive quarter, with sales of each up 172% and 68%, respectively.
Below is a chart illustrating the company’s sales on a quarterly basis.
The favorable results led LLY to increase its FY25 revenue and adjusted EPS guidance, with its gross margin also moving higher to 84.3% vs the 80.8% mark in the year-ago period. Analysts have revised EPS expectations positively following the release, a bullish sign concerning near-term price action.
Image Source: Zacks Investment Research
Several directors and the CEO have purchased shares post-earnings, likely a reflection of their confidence in the long-term outlook.
Bottom Line
The 2025 Q2 earnings season is slowly grinding to a halt, which has been largely positive so far. Earnings expectations for the current period (Q3) have trickled higher, a positive development.
And throughout the Q2 cycle, several companies – Eli Lilly (LLY - Free Report) and Palantir (PLTR - Free Report) – partly stole the spotlight, reporting strong results and upping their guidance.